Search Results for: formulation development amorphous dispersion formu
Articles
Capsugel Unveils New Facility; Significantly Expands Capability July 6, 2015
Capsugel recently announced it has completed construction of a new pharmaceutical spray-dried dispersion (SDD) commercial manufacturing facility at its site...SPECIAL FEATURE – Excipients: Enhancing the New, Poorly Soluble APIs June 1, 2015
Contributor Cindy H. Dubin interviews several excipient manufacturers who share their insights about the role excipients play in formulating and manufacturing drugs for improved bioavailability, solubility, and delivery.
SPECIAL FEATURE – Bioavailability & Solubility: A Demand for Enhanced Technologies & Materials is Spurring Innovation March 3, 2015
Contributor Cindy H. Dubin spoke with several contract research/manufacturing organizations on how they are successfully overcoming solubility/bioavailability challenges, such as matching APIs to formulations and choosing the best excipients.
Ascendia Advances, Successfully Applies Nano-Emulsion Technology Platform September 9, 2014
Ascendia Pharmaceuticals, a start-up specialty pharmaceutical company in the business of providing formulation technologies and product development services for poorly...BIOAVAILABILITY ENHANCEMENT – Diffusion of Innovation & the Adoption of Solubilization Technologies: Observations of Trends & Catalysts June 5, 2014
Marshall Crew, PhD, says that although diffusion processes of innovative products and services have been studied extensively for nearly 45 years, it seems reasonable that we might learn from others’ observations, and the frameworks they’ve developed to model diffusion of technology for the adoption of bioavailability platforms.
EXECUTIVE INTERVIEW – The Integration of Bend Research With Capsugel Dosage Form Solutions (DFS) June 4, 2014
Drug Development Executive: Rod Ray, former Bend Research CEO and now a member of Capsugel’s Scientific and Business Advisory Board, talks about the enhanced capabilities of Capsugel DFS and the advantages offered to companies developing new and/or enhanced medicines.
BIOAVAILABILITY ENHANCEMENT – Analysis of the Historical Use of Solubilization Technologies March 5, 2014
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
BIOAVAILABILITY ENHANCEMENT – A New Year for Solubility Enhancement January 7, 2014
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part III of III November 19, 2013
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., concludes his multiple-part series discussing today’s most challenging issues in solubility.
EXECUTIVE INTERVIEW – Catalent Applied Drug Delivery Institute: Helping to Get Better Drugs to Waiting Patients, Encouraging the Adoption of Advanced Delivery Technologies November 19, 2013
Drug Development Executive: Kurt Nielsen, PhD, CTO & SVP, Innovation & Growth, and Founding Institute Board Member, discusses the Institute, its goals, structure, and activities.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part II of III October 15, 2013
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part I of III September 5, 2013
In the past two columns, The Second Quadrant focused on excipients and the roles they play in the quest to...BIOAVAILABILITY ENHANCEMENT – Out of the Shadows: Excipients Take the Spotlight; Part 2 of 2 July 10, 2013
In June’s edition of The Second Quadrant, we heard from leading excipient providers about challenges faced directly related to formulating...BIOAVAILABILITY ENHANCEMENT – Out of the Shadows: Excipients Take the Spotlight; Part 1 of 2 June 10, 2013
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
Hovione Announces a Co-Promotion & Collaboration Agreement April 8, 2013
Hovione recently announced a co-promotion and collaboration agreement with Ligand to provide Hovione's customers efficient access to Captisol technology. Captisol,...EXECUTIVE INTERVIEW – Agere: Solubilization: Accessing Broader Chemistries by Integrating Fundamental Science With Automation for Greater Predictability March 27, 2013
Drug Development Executive: Marshall Crew, President & CEO of Agere, discusses how the company is taking a different approach that leverages expertise, but relies heavily on the principles of physical chemistry to enable automation.
12/5/2012 November 29, 2012
Curis Announces Several Major Announcements Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group,...EXECUTIVE INTERVIEW – Hovione: New technologies in Particle Design October 12, 2012
Dr. Colin Minchom, VP of Hovione’s Particle Design business unit, discusses how the company is evolving and adapting in the current market and reviews its new Particle Design offering.
10/3/2012 October 1, 2012
Actinium Announces Multi-Million Financing Actinium Pharmaceuticals, Inc. recently announced it has engaged Laidlaw & Company (UK) Ltd. and launched a...Hovione Expands Offering to Solve Bioavailability & Other Delivery Challenges October 1, 2012
Hovione recently announced the expansion of its solutions to solve issues of poor bioavailability, patient acceptability, and the enabling of...Tech Showcase
Nanoparticle Formulations
Ascendia Pharmaceuticals is a contract development and manufacturing (CDMO) company offering services for formulation development of poorly soluble drugs and...
